CEB2: COST-EFFECTIVENESS OF MENINGOCOCCAL VACCINE IN THE UK  by Brown, RE et al.
58 Abstracts
CAN4
IS PRIOR COMMUNITY ANTIBIOTIC 
TREATMENT OF PATIENTS HOSPITALISED 
WITH LOWER RESPIRATORY TRACT 
INFECTION ASSOCIATED WITH REDUCED IN-
HOSPITAL MORTALITY AND LENGTH OF STAY?
Steinke D, Donnan P, MacDonald T, Davey P
Medicines Monitoring Unit, Ninewells Hospital, Dundee, 
Scotland
BACKGROUND: A previous study (Davey et al, Value
in Health 1999, 2:333–341) suggested that prior commu-
nity antibiotic therapy is associated with reduced in-hos-
pital mortality. OBJECTIVES: To confirm the original
finding in a larger study and to test the hypothesis that
patients who received prior antibiotic treatment would
also have lower hospital length of stay. METHODS: Pa-
tients with hospital discharge codes including lower res-
piratory infections (LRTI) or chronic obstructive airways
disease (COAD) were identified at three acute hospitals
from ICD9 codes in the Scottish Morbidity Records
(SMR) for 1993 to 1995. Patients with episodes starting
48h after admission were excluded because they were
likely to have nosocomial pneumonia. Prior antibiotic
treatment was defined as any treatment in the 28 days be-
fore hospitalization. RESULTS: There were 1285 pa-
tients with LRTI alone and 1603 with COAD of whom
366 also had LRTI. Antibiotic treatment occurred before
hospitalization in 35% of patients with LRTI alone and
41% of patients with COAD. Patients with LRTI alone
who received community antibiotics were less likely to
die in the 50 days after admission: relative risk 0.73
(95% CI 0.61–0.87) unadjusted and 0.83 (0.69–1.00)
adjusted for age, sex and social deprivation. There was
no difference in 50 day mortality between COAD pa-
tients who did or did not receive community antibiotics.
Age was the only variable that was significantly associated
with length of stay in the LRTI patients. Length of stay
was not different for patients who received community an-
tibiotics, either in the entire cohort (P  0.25) or in the
832 patients who were discharged alive (P  0.81). CON-
CLUSION: This study confirmed that community antibi-
otic treatment is associated with reduced 50 day mortality
for patients admitted with LRTI, but not COAD. How-
ever, there was no significant association between commu-
nity antibiotic treatment and length of hospital stay.
Cost-Effectiveness/Cost-Benefit Analyses CEB 
(Session 1)
CEB1
PHARMACOGENOMICS: EVALUATING THE 
ECONOMIC IMPACT
Veenstra DL, Higashi MK
University of Washington, Seattle, WA, USA
OBJECTIVE: Pharmacogenomics, the individualization
of drug therapy based on genetic information, promises
to change the clinical use of therapeutics and influence
the drug development process, however the potential
clinical and economic outcomes of pharmacogenomics is
not clear. Our objective is to develop a framework for
evaluating the cost-effectiveness of genetic-guided drug
therapy. METHODS: We reviewed examples of currently
practiced non-genetically based individualization of drug
therapy. These examples were classified into two catego-
ries: dose modification and drug selection. The costs, re-
sponse characteristics, and implementation strategy for
the tests were evaluated. We also evaluated the therapeu-
tics and diseases for which these tests were used to deter-
mine which characteristics led to the implementation of
individualized drug therapy. We then developed a frame-
work for evaluating the cost-effectiveness of pharmaco-
genomics and applied it to examples of currently debated
pharmacogenomic strategies. RESULTS: Drug monitor-
ing is typically employed only for drugs with a narrow
therapeutic index, whereas drug selection is often em-
ployed with the use of antimicrobials, where drug effec-
tiveness is highly dependent on diagnostic information.
The economic and, importantly, the time cost are impor-
tant determinates of the usefulness of testing procedures.
The prevalence of polymorphisms, the penetrance of dis-
ease-related genes, and the magnitude of relative risk will
also have a significant impact on the usefulness of genetic
diagnostics. We found that some commonly cited exam-
ples of potential applications of pharmacogenomics do not
fulfill these criteria. Our analysis suggests that drug-gene
interactions such as warfarin-CYP2C9, 6-mercaptopu-
rine-TPMT, and COX-II inhibitors-Familial Adenomatous
Polyposis (FAP) have the potential to produce cost-effec-
tive results. CONCLUSIONS: The use of pharmacoge-
nomics to improve the cost-effectiveness of pharmaceuti-
cals requires careful evaluation and will not be useful in
all cases.
CEB2
COST-EFFECTIVENESS OF MENINGOCOCCAL 
VACCINE IN THE UK
Brown RE1, Sorensen S1, Batista C1, Nuijten M2
1MEDTAP International Inc., Bethesda, MD, USA; 2MEDTAP 
International Inc., Amsterdam, The Netherlands
OBJECTIVE: Conduct cost-effectiveness analysis of vac-
cinating children in the UK under one year or aged 1 to 4
years against meningococcal serotype C disease. METH-
ODS: A model was developed to estimate the number of
cases and deaths avoided and years of life gained over a
lifetime. The incidence of disease was based upon menin-
gococcal disease reported in the UK and assumes 34% is
serotype C. The vaccine efficacy was assumed to be 90%
based on clinical evidence. Estimated direct medical re-
sources consumed in the acute management of meningo-
coccal disease, acute, and short-term sequelae were ob-
tained from physician opinion. The costs associated with
the management of hearing loss, cerebral palsy, seizures,
and mental retardation over the long term were obtained
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from published studies conducted in the UK and included
direct medical and indirect costs. Resource unit costs
were obtained from published sources. Vaccination pro-
gram costs were included. Future costs were discounted
5%. RESULTS: The incremental cost per year of life
gained in the under one year old group was £4,280 with-
out discounting the benefit and £6,357 with discounting.
The incremental cost per life year gained in the cohort
aged 1–4 years was £1,060 without discounting the bene-
fit and £1,557 with discounting the years of life gained.
Both age group ratios increase as the costs of managing
acute and long-term sequelae are decreased. Assuming a
higher proportion of meningococcal infections are sero-
type C (40%) results in ratios of £3,146 and £470 for the
younger and older groups, respectively. CONCLU-
SIONS: The cost-effectiveness ratios for vaccinating chil-
dren under age 1 and between ages 1 and 4 fall within the
generally acceptable range of costs for adopting new
technology.
CEB3
COST-EFFECTIVENESS OF PREVENTION OF 
CORONARY HEART DISEASE (CHD) WITH 
SIMVASTATIN IN POLAND
Kuzniar J, Orlewska E, Hermanowski T, Romanczuk W, 
Splawinski J
Institute of Drugs, Warsaw, Poland
Cost-effectiveness of secondary prevention of CHD in the
Western World with simvastatin (S) is well established.
OBJECTIVE: Cost-effective evaluation of secondary pre-
vention of CHD with simvastatin in the Polish setting
with the health care system in a transition period.
METHOD: It was assumed that the effects of S in Polish
patients would be the same as those of Scandinavian Sim-
vastatin Survival Study. Direct medical costs were ob-
tained from Polish sources. ICER was calculated dividing
net costs by years of life gained during 5.4 years of treat-
ment with S projected over an average life expectancy of
10 years. One-way and multi-way sensitivity analyses
were performed. Frequency of hospitalizations, costs of
hospitalizations, and life-years saved were the variables
used in Monte Carlo analysis. RESULTS: Net cost/pa-
tient (discounted at 5%) was $2478.5; cost per life-years
saved (LYS) was $10,326.8 (mean ICER from Monte
Carlo analysis was $10,243.9). ICER value was highly
sensitive to the price of S and relatively insensitive to the
value of savings (including saving of PTCA, CABG, myo-
cardial infarction, and hospitalisations). The latter, in
Polish settings, amounted to only 8.2% of drug cost (in
Sweden 30%). The cost per LYS is higher than the cost
of 1 year of hemodialysis and about 3 times higher than
the GNP per capita ($3527.6) in Poland. CONCLU-
SIONS: Results indicate that secondary prevention of
CHD in patients with mild hypercholesterolemia with S
in Poland is hardly cost-effective due to the low value of
savings. The value of medical services in Poland is proba-
bly underestimated.
CEB4
THE COST-EFFECTIVENESS OF FIXED-DOSE 
COMBINATION OF DICLOFENAC AND 
MISOPROSTOL IN PREVENTION OF NSAID-
INDUCED ULCERS IN RHEUMATOID ARTHRITIS 
PATIENTS IN POLAND
Orlewska E
Unimed Centre for Pharmacoeconomics, Warsaw, Poland
OBJECTIVES: Cost-effectiveness estimation of treatment
with a fixed-dose combination of diclofenac and miso-
prostol (FDC D-M) 50 mg/200 mcg bid compared with
diclofenac (D) 50 mg bid in prevention of NSAID-induced
ulcers in rheumatoid arthritis (RA) patients in Poland.
METHODS: A decision model for FDC D-M in the Pol-
ish health care context was developed, based on epidemi-
ological and clinical data from the literature and local
data on health care resource utilization and unit cost.
Only direct medical costs are analyzed. The perspective
of health care payers (sickness funds  patients) is taken.
The time horizon is 3 months, but consequences of a
longer time horizon are discussed. Cost-effectiveness was
calculated for the treatment of all RA patients and risk
groups only. Effectiveness was expressed in life-years
saved. The cost-effectiveness threshold, calculated on basis
of 1-year of haemodialysis treatment cost ($15,600 US)
or national GDP per head at PPP ($6300 US), was sug-
gested to asses whether the FDC D-M therapy should be
adopted. RESULTS: Analysis showed that FDC D-M treat-
ment in RA patients gives additional life years for extra
cost. In all RA patients (aged 65) 1 LYG costs $33,700
US. Cost per LYG was below the suggested cost-effective-
ness threshold only in patients at high risk (history of
peptic ulcer disease or GI bleeding, disability—mHAQ
1.5, concomitant antacid therapy). One-way sensitivity
analysis showed that outcomes are sensitive to changes
in: price differences between FDC-D-M and D, percent
ulcers, and the efficacy of misoprostol. CONCLUSION:
FDC D-M treatment in Poland is cost-effective only in
RA patients at high risk for NSAID-induced ulcers.
Drug Utilization/Compliance DUC
DUC1
DRUG UTILIZATION OF CISAPRIDE AND 
CONTRAINDICATED DRUGS IN A US MANAGED 
CARE POPULATION
Guo JJ1, Jones JK1, Fife D2, Curkendall S1, Goehring E1, She D1
1The Degge Group, Ltd., Arlington, VA, USA; 2Janssen 
Pharmaceutica, Titusville, NJ, USA
Cisapride, an oral GI prokinetic agent, was reported to
cause serious cardiac arrhythmia in patients who received
imidazole antifungals, macrolide antibiotics, or protease
inhibitors. Several label changes and dear Dr. letters were
sent to prescribers in February and October 1995, and
June 1998. OBJECTIVE: To quantify the effectiveness of
label changes and dear Dr. letters on patient medication
